Topic: prefrontal dysfunction

Current therapies for Alcohol Use Disorder (AUD) exhibit significant variability in effectiveness, resulting in high relapse rates. Addressing this challenge requires a precision medicine approach incorporating biomarkers responsive to novel treatments. A promising approach involves bioelectronic devices utilising neuroelectric signatures of impaired prefrontal function, a key feature in AUD resulting in diminished inhibitory control over compulsive behaviour and increased vulnerability to relapse. Thus, we reason that event-related potentials and neural oscillations are valuable biomarkers fo